Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and ...
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...
Just because a research project sounds like a waste of money to people who know nothing of the topic, doesn’t mean it won’t ...
The NPM-115 device is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Vivani says the drug has demonstrated good drug release both in ...
Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. How to Spot the Market Bottom: Matt Maley has navigated ...
Hosted on MSN1mon
Study Finds Exenatide Not Beneficial for Parkinson DiseaseFRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback